Sprycel: The Promise of Dasatinib in Targeted Cancer Therapy
Sprycel is a targeted therapy that works by binding to and inhibiting the BCR-ABL tyrosine kinase. This kinase is constitutively active in CML due to the Philadelphia chromosome abnormality. By blocking this kinase, Dasatinib is able to inhibit the downstream signaling pathways that drive the overproduction of white blood cells in CML. Inhibition of BCR-ABL leads to apoptosis of CML cells and halts disease progression. Importantly, Dasatinib remains effective against many of the mutations that can cause resistance to first-generation tyrosine kinase inhibitors like imatinib.

Get more insights on, Sprycel
(https://fortunetelleroracl...

#CoherentMarketInsights #PediatricIndicationsforSprycel #SprycelCombinationTherapies #EmergingMarketsforSprycel #GenericCompetitionforSprycel #AdverseEventsinSprycelTherapy